Journal of Rheumatic Diseases最新文献

筛选
英文 中文
Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study. 更正:韩国类风湿关节炎患者开始生物疗法后的治疗顺序:一项全国性回顾性队列研究。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-10-01 DOI: 10.4078/jrd.22.0024C
Min Jung Kim, Jun Won Park, Sun-Kyung Lee, Yumi Jang, Soyoung Kim, Matthias Stoelzel, Jonathan Lumen Chua, Kichul Shin
{"title":"Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study.","authors":"Min Jung Kim, Jun Won Park, Sun-Kyung Lee, Yumi Jang, Soyoung Kim, Matthias Stoelzel, Jonathan Lumen Chua, Kichul Shin","doi":"10.4078/jrd.22.0024C","DOIUrl":"https://doi.org/10.4078/jrd.22.0024C","url":null,"abstract":"<p><p>[This corrects the article on p. 26 in vol. 30, PMID: 37476522.].</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 4","pages":"263"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of disease activity index in rheumatoid arthritis management in Korea. 疾病活动指数在韩国类风湿关节炎管理中的应用。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-10-01 Epub Date: 2024-08-02 DOI: 10.4078/jrd.2024.0077
Se Rim Choi, Soo-Kyung Cho, Yoon-Kyoung Sung
{"title":"Application of disease activity index in rheumatoid arthritis management in Korea.","authors":"Se Rim Choi, Soo-Kyung Cho, Yoon-Kyoung Sung","doi":"10.4078/jrd.2024.0077","DOIUrl":"10.4078/jrd.2024.0077","url":null,"abstract":"<p><p>Effective management of rheumatoid arthritis (RA) necessitates the accurate measurement of disease activity using a treat-to-target strategy established as a cornerstone approach. Disease activity assessment tools such as the Disease Activity Score in 28 joints (DAS28), Simplified Disease Activity Index, Clinical Disease Activity Index, and Routine Assessment of Patient Index Data 3 have been internationally validated and recognised. In Korea, the government initiated a quality assessment program mandating routine measurement of DAS28 to ensure high-quality RA management. However, whether the DAS28 is the most suitable disease activity measurement tool in the Korean clinical environment is a topic worth considering. In this review, we comprehensively examined disease activity measurement tools and their performance in the Korean context. We also propose a new strategy for measuring RA disease activity, tailored to the different situations encountered by physicians in routine clinical practice. This review may contribute to the improvement of the quality of care for patients with RA in Korea.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 4","pages":"193-199"},"PeriodicalIF":2.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effectiveness of tumor necrosis factor-α blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index. 肿瘤坏死因子-α受体阻滞剂疗法对常规治疗失败的轴性脊柱关节炎患者的疗效:一项以 ASAS 健康指数改善情况为重点的比较研究。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2024-04-29 DOI: 10.4078/jrd.2024.0029
Ah-Ra Choi, Ki-Jeong Park, Ji-Hyoun Kang, Yu Jeong Lee, Hyun Hee Jang, Moon-Ju Kim, Tae-Jong Kim
{"title":"The effectiveness of tumor necrosis factor-α blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index.","authors":"Ah-Ra Choi, Ki-Jeong Park, Ji-Hyoun Kang, Yu Jeong Lee, Hyun Hee Jang, Moon-Ju Kim, Tae-Jong Kim","doi":"10.4078/jrd.2024.0029","DOIUrl":"10.4078/jrd.2024.0029","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study is to evaluate the impact of tumor necrosis factor (TNF)-α blocker therapy on the Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) among patients who have failed conventional nonsteroidal anti-inflammatory drugs.</p><p><strong>Methods: </strong>A comparative study was conducted involving axial spondyloarthritis (axSpA) patients treated with either TNF-α blocker or conventional therapy. Patient data, including demographics, disease characteristics, and ASAS-HI scores, were collected before and after treatment. Statistical analysis was performed to compare changes in ASAS-HI scores between the TNF-α blocker and the conventional therapy group.</p><p><strong>Results: </strong>The study population consisted of patients with axSpA, with a mean age of 38.3 years in conventional treatment group and 29.3 years in TNF-α blocker group. Most variables, including C-reactive protein levels, other comorbidities, and disease assessment scores showed no significant difference between groups. Longitudinal analysis within each treatment group from Week 0 to 12 showed no significant change in the conventional treatment group, whereas the TNF-α blocker group experienced a significant reduction in ASAS-HI scores, demonstrating the effectiveness of the treatment. The TNF-α blocker group exhibited a significantly greater improvement in ASAS-HI scores compared to the conventional therapy group. The Bath Ankylosing Spondylitis Functional Index and the Bath Ankylosing Spondylitis Disease Activity Index demonstrated strong positive correlations with ASAS-HI scores, indicating higher disease activity and functional limitation are associated with worse health outcomes in patients.</p><p><strong>Conclusion: </strong>The research demonstrates that ASAS-HI scores significantly improve with TNF-α blocker therapy in axSpA patients, underscoring ASAS-HI's effectiveness as a tool for evaluating drug responses.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"171-177"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus. 单基因狼疮患儿自身抗体谱的临床特征和预后价值。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2023-12-14 DOI: 10.4078/jrd.2023.0065
Sulaiman M Al-Mayouf, Alaa Hamad, Wassima Kaidali, Raghad Alhuthil, Alhanouf Alsaleem
{"title":"Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus.","authors":"Sulaiman M Al-Mayouf, Alaa Hamad, Wassima Kaidali, Raghad Alhuthil, Alhanouf Alsaleem","doi":"10.4078/jrd.2023.0065","DOIUrl":"10.4078/jrd.2023.0065","url":null,"abstract":"<p><strong>Objective: </strong>To report the frequency of selected autoantibodies and their associations with clinical features in Arab children with monogenic lupus.</p><p><strong>Methods: </strong>This study was retrospective single-center study of genetically confirmed monogenic lupus cases at childhood lupus clinic at King Faisal Specialist Hospital and Research Center, from June 1997 to July 2022. We excluded familial lupus without genetic testing and patients with insufficient data. Collected data comprised clinical and laboratory findings, including the autoantibody profile, which included the anti-double-stranded DNA (anti-dsDNA), anti-Smith, anti-Sjögren's-syndrome-related antigen A (anti-SSA), anti-Sjögren's-syndrome-related antigen B (anti-SSB), and antiphospholipid (APL) antibodies. Also, disease activity and accrual disease damage were collected at the last follow-up visit.</p><p><strong>Results: </strong>This study enrolled 27 Arab patients (14 males) with a median age of 11 years (interquartile range 8.0~16 years), with 63% having early-onset disease. The consanguinity rate and family history of lupus were high (74.1% and 55.6%, respectively). The most frequent clinical features were hematological (96.3%), fever (81.5%), mucocutaneous lesions (85.2%), and renal (66.7%). The frequency of the APL antibodies was 59.3%, anti-dsDNA was 55.6%, and anti-Smith and anti-SSA were 48.2% and 44.4%, respectively. Moreover, dsDNA antibodies were significantly associated with musculoskeletal complaints (p<0.05). Likewise, both anti-Smith and anti-SSA antibodies were linked to failure to thrive and recurrent infections in the univariate analysis (p<0.05).</p><p><strong>Conclusion: </strong>Our study reveals autoantibody frequencies and their association with clinical and prognostic in a substantial monogenic lupus cohort. Distinct clinical manifestations and prognosis association with certain autoantibodies support the idea that monogenic lupus is a distinctive form of lupus. Larger studies needed to validate these findings.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"143-150"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jaccoud's arthropathy in osteogenesis imperfecta. 成骨不全症中的雅库德关节病
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2024-02-01 DOI: 10.4078/jrd.2023.0090
Frederico Rajão Martins, Margarida Lucas Rocha, Ana Teodósio Chícharo, Vítor Silvestre-Teixeira
{"title":"Jaccoud's arthropathy in osteogenesis imperfecta.","authors":"Frederico Rajão Martins, Margarida Lucas Rocha, Ana Teodósio Chícharo, Vítor Silvestre-Teixeira","doi":"10.4078/jrd.2023.0090","DOIUrl":"10.4078/jrd.2023.0090","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"188-189"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid-free adalimumab-cyclophosphamide combination therapy for acute phase neuro-Behçet's disease: a case report. 不含皮质类固醇的阿达木单抗-环磷酰胺联合疗法治疗急性期神经性贝赫切特病:病例报告。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2024-02-02 DOI: 10.4078/jrd.2023.0069
Ji Hyoun Kim, Sang Wan Chung, Yun Jong Lee
{"title":"Corticosteroid-free adalimumab-cyclophosphamide combination therapy for acute phase neuro-Behçet's disease: a case report.","authors":"Ji Hyoun Kim, Sang Wan Chung, Yun Jong Lee","doi":"10.4078/jrd.2023.0069","DOIUrl":"10.4078/jrd.2023.0069","url":null,"abstract":"<p><p>Neuro-Behçet's disease (NBD) represents a significant complication of Behçet's syndrome, potentially leading to elevated mortality and disability rates. The standard treatment for parenchymal NBD typically entails administering high-dose corticosteroids to prompt rapid-onset effects, coupled with immunosuppressants to prevent subsequent relapses. A 48-year-old male with NBD presented with progressively worsening dysarthria over 9 months. This patient experienced increased intraocular pressure while using glucocorticoids, which worsened his pre-existing glaucoma. The patient had a prior diagnosis of NBD and presented with progressive dysarthria over a period of nine months, leading to a brain magnetic resonance imaging (MRI) scan. The brain MRI revealed multifocal punctate high signal intensities in the left frontoparietal area, insula, and basal ganglia. Instead of the standard steroid pulse therapy, the patient received adalimumab-cyclophosphamide combination as an alternative induction therapy. Subsequent serial brain MRI scans exhibited no emergence of new lesions, and the patient remained devoid of clinical relapses even after 17 months from the commencement of induction treatment. Adalimumab-cyclophosphamide combination could be used as a corticosteroid-free induction strategy for NBD. Further investigations are warranted to establish the most suitable combination regimen.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"178-181"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells: beyond challenges to success. 重组人骨形态发生蛋白-2 和骨保护蛋白-Fc 在 MC3T3-E1 细胞中的作用:从挑战到成功。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 DOI: 10.4078/jrd.2024.0079
Chang Hoon Lee
{"title":"Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells: beyond challenges to success.","authors":"Chang Hoon Lee","doi":"10.4078/jrd.2024.0079","DOIUrl":"10.4078/jrd.2024.0079","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"133-134"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The monocyte-to-high-density lipoprotein-cholesterol ratio at diagnosis is associated with cerebrovascular accident during follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis. 抗中性粒细胞胞浆抗体相关性血管炎患者确诊时的单核细胞与高密度脂蛋白胆固醇比率与随访期间的脑血管意外有关。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2024-03-12 DOI: 10.4078/jrd.2024.0001
Jang Woo Ha, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
{"title":"The monocyte-to-high-density lipoprotein-cholesterol ratio at diagnosis is associated with cerebrovascular accident during follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis.","authors":"Jang Woo Ha, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee","doi":"10.4078/jrd.2024.0001","DOIUrl":"10.4078/jrd.2024.0001","url":null,"abstract":"<p><strong>Objective: </strong>In this study, the association between the monocyte-to-high-density lipoprotein cholesterol ratio (MHR) at diagnosis and poor outcomes of atherosclerosis-related antineutrophil cytoplasmic antibody-associated vasculitis (AAV) during follow-up in patients with AAV was investigated.</p><p><strong>Methods: </strong>This retrospective study included 138 patients diagnosed with AAV. Their comprehensive medical records were meticulously reviewed. All-cause mortality, cerebrovascular accident (CVA), and acute coronary syndrome (ACS) were evaluated as atherosclerosis-related poor outcomes of AAV. MHR was obtained by dividing monocyte counts (/mm3) by high-density lipoprotein cholesterol (mg/dL) levels.</p><p><strong>Results: </strong>The median age of the 138 patients was 58.3 years with 44 being male (31.9%). Among the 138 patients, 11 (8.0%) died, and 11 (8.0%) and 9 (6.5%) had CVA, and ACS, respectively. MHR at diagnosis was significantly correlated with the Birmingham vasculitis activity score, erythrocyte sedimentation rate, and C-reactive protein at diagnosis. Among the three poor outcomes of AAV, only CVA during follow-up was significantly associated with MHR at diagnosis, and thus, only CVA was considered an atherosclerosis-related poor outcome of AAV. In the multivariable Cox hazards model analysis, MHR (hazard ratio [HR] 1.195) and serum albumin (HR 0.203) at diagnosis were independently associated with CVA during follow-up. Additionally, patients with MHR at diagnosis ≥3.0 exhibited a significantly higher risk for CVA and lower cumulative CVA-free survival rate than those with MHR at diagnosis <3.0.</p><p><strong>Conclusion: </strong>This study is the first to demonstrate clinical implications of MHR suggesting that MHR at diagnosis is significantly and independently associated with CVA during follow-up in patients with AAV.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"151-159"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the diagnostic odyssey: stimulator of interferon gene-associated vasculopathy with onset in infancy in a 30-year-old female. 揭开诊断奥德赛的神秘面纱:一名 30 岁女性婴儿期发病的干扰素基因相关血管病变刺激因子。
IF 2.2
Journal of Rheumatic Diseases Pub Date : 2024-07-01 Epub Date: 2024-04-09 DOI: 10.4078/jrd.2023.0075
Hae Ryung Kim, Seon Hee Lim, Ji Soo Park, Dong In Suh, Seungbok Lee, Soo Yeon Kim, Jong Hee Chae, Seong Heon Kim
{"title":"Unraveling the diagnostic odyssey: stimulator of interferon gene-associated vasculopathy with onset in infancy in a 30-year-old female.","authors":"Hae Ryung Kim, Seon Hee Lim, Ji Soo Park, Dong In Suh, Seungbok Lee, Soo Yeon Kim, Jong Hee Chae, Seong Heon Kim","doi":"10.4078/jrd.2023.0075","DOIUrl":"10.4078/jrd.2023.0075","url":null,"abstract":"<p><p>Stimulator of interferon gene (STING)-associated vasculopathy with onset in infancy (SAVI) is an extremely rare autoinflammatory disease. We present the case of a female Korean patient with early-onset interstitial lung disease who was initially suspected to have systemic lupus erythematosus (SLE) but was ultimately diagnosed with SAVI. The patient exhibited signs of interstitial lung disease and cutaneous manifestations before the age of 1 year and continued to have recurrent fever accompanied by pulmonary infiltrates. Based on positive findings for antibodies associated with SLE, such as antinuclear antibodies and anti-double-stranded DNA, the pulmonary involvement was considered a manifestation of SLE. Another significant symptom was recurrent skin ulceration, which led to partial spontaneous amputation of most of the toes due to inflammation. Given the early onset of interstitial lung disease, severe skin ulcers, and symptoms resembling SLE, autoinflammatory syndrome, especially SAVI was suspected. Following confirmation by genetic testing at age 29 years, the patient was started on tofacitinib, a Janus kinase inhibitor. Despite the prolonged use of multiple immunosuppressive therapies, the patient's lung condition continued to worsen, ultimately requiring lung transplantation. This observational report highlights the importance of considering SAVI as a potential diagnosis when manifestations of interstitial lung disease are observed during infancy. Early proactive treatment is crucial for lung involvement, as this can have long-term effects on patient's prognosis.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 3","pages":"182-187"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells. 重组人骨形态发生蛋白-2 和骨保护蛋白-Fc 在 MC3T3-E1 细胞中的作用。
IF 2
Journal of Rheumatic Diseases Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI: 10.4078/jrd.2023.0043
Sang-Hyon Kim, Hye-Jung Choi, Sang-Min Lee, Dae Sung Yoon, Chang-Nam Son
{"title":"Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells.","authors":"Sang-Hyon Kim, Hye-Jung Choi, Sang-Min Lee, Dae Sung Yoon, Chang-Nam Son","doi":"10.4078/jrd.2023.0043","DOIUrl":"10.4078/jrd.2023.0043","url":null,"abstract":"<p><strong>Objective: </strong>We compared the osteoblastogenesis by serially administrating recombinant human bone morphogenetic protein-2 (rhBMP-2) and osteoprotegerin-immunoglobulin Fc segment complex (OPG-Fc).</p><p><strong>Methods: </strong>The MC3T3-E1 preosteoblast cell line was differentiated for 1, 3, and 7 days with a treatment of OPG-Fc in 10~200 ng/mL concentration and the cell viability was evaluated by Cell Counting Kit-8 analysis. The level of differentiation from MC3T3-E1 cells to osteoblasts was determined by alkaline phosphatase activity. The level of runt domain-containing transcription factor 2 (Runx2) and osteopontin (OPN) manifestation, involved in osteoblast differentiation, was examined by real-time polymerase chain reaction and western blotting.</p><p><strong>Results: </strong>During MC3T3-E1 cell differentiation, the differentiation level was high with 1-day treatment using 100 ng/mL OPG-Fc. The treatment with 50 ng/mL rhBMP-2 for 7 days, followed by 1-day treatment with 100 ng/mL OPG-Fc produced the highest differentiation level, which was approximately 5.3 times that of the control group (p<0.05). The expression of Runx2 mRNA significantly increased, reaching 2.5 times the level of the control group under the condition of 7-day treatment with rhBMP-2 and 1-day treatment with OPG-Fc (p<0.001). The expression of Runx2 protein significantly increased to approximately 5.7 times that of the control group under the condition of 7-day treatment with rhBMP-2, followed by 1-day treatment with OPG-Fc (p<0.01). The expression of OPN protein showed no change from that of the control group under various conditions of rhBMP-2 and OPG-Fc combinations.</p><p><strong>Conclusion: </strong>These results imply that the treating preosteoblasts with rhBMP-2 first and then with OPG-Fc increased osteoblast differentiation efficacy.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"31 2","pages":"79-85"},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信